Published December 5, 2012 | Version v1
Journal article

Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells

  • 1. Institute of Radiation Biology, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Muenchen (Germany)
  • 2. Institute of Pathology, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Muenchen (Germany)
  • 3. Research Unit of Radiation Cytogenetics, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Muenchen (Germany)
  • 4. Department of Oncology and Pathology, Karolinska Institute and Hospital, Stockholm (Sweden)
  • 5. Radiation Biology, Institute of Radiation Oncology, Technical University Munich, Munich (Germany)

Description

There is evidence that the extent of the G2/M arrest following irradiation is correlated with tumour cell survival and hence therapeutic success. We studied the regulation of cellular response to radiation treatment by miR-21-mediated modulation of cell cycle progression in breast cancer cells and analysed miR-21 expression in breast cancer tissue samples with long-term follow up. The miR-21 expression levels were quantified (qRT-PCR) in a panel of 86 cases of invasive breast carcinomas in relation to metastasis free survival. The cellular radiosensitivity of human breast cancer cells after irradiation was determined comparing two cell lines (T47D and MDA-MB-361) by cell proliferation and colony forming assays. The influence of miR-21 overexpression or downregulation on cell cycle progression and G2/M checkpoint arrest after irradiation was assessed by flow cytometric analysis. The expression of miR-21 was transiently increased 8 hours after irradiation in the radioresistant T47D cells and significantly changed with lower extent in radiosensitive MDA-MB-361 cells. Anti-miR-21 treated breast cancer cells failed to exhibit the DNA damage-G2 checkpoint increase after irradiation. Apoptotic activity was significantly enhanced from 7% to 27% in T47D cells and from 18% to 30% in MDA-MB-361 cells 24 hours after 5 Gy irradiation. Additionally, we characterized expression of miR-21 in invasive breast carcinomas. In comparison to non-cancerous adjacent breast tissue, tumours samples had increased miR-21 expression that inversely correlated with the distant metastases-free survival of patients (p = 0.029). Our data indicate that miR-21 expression in breast cancer cells contributes to radiation resistance by compromising cell cycle progression. These data point to the potential of combining radiotherapy with an anti-miR-21 as a potent G2/M check point inhibitor in overcoming radiation resistance of tumours

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-7-206; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573984

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
7
Journal Page Range
p. 206
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47062056
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; CELL CYCLE; CELL PROLIFERATION; GY RANGE 01-10; IRRADIATION; MAMMARY GLANDS; RADIOSENSITIVITY; RADIOTHERAPY
Descriptors DEC
ABSORBED DOSE RANGE; BODY; DISEASES; GLANDS; GY RANGE; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIATION DOSE RANGES; RADIOLOGY; SENSITIVITY; THERAPY

Optional Information

Copyright
Copyright (c)2012 Anastasov et al.
Notes
PMCID: PMC3573984; PUBLISHER-ID: 1748-717X-7-206; PMID: 23216894; OAI: oai:pubmedcentral.nih.gov:3573984; licensee BioMed Central Ltd.